A single center open-label uncontrolled study to investigate tumour response and vascularization changes in neoadjuvant therapy with BAY 43-9006 [sorafenib] single agent therapy in patients with operable renal cell cancer.

Trial Profile

A single center open-label uncontrolled study to investigate tumour response and vascularization changes in neoadjuvant therapy with BAY 43-9006 [sorafenib] single agent therapy in patients with operable renal cell cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2009

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Sep 2009 Additional trial lead centres as reported by Netherlands Trial Register record.
    • 23 Sep 2009 Status changed from completed to planning as reported by Netherlands Trial Register record.
    • 22 Sep 2009 New source identified and integrated (Netherlands Trial Register).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top